Drug intelligence / Profile preview

Zymawin

Development stage: Unknown
Lead developer: Amox Pharmaceuticals
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Oral, Topical

Overview

Zymawin is a digestive enzyme formulation developed and marketed by Amox Pharmaceuticals, typically presented in a drop dosage form. It is designed to assist in the digestion of carbohydrates and proteins, making it useful for treating dyspepsia, flatulence, and other digestive disturbances. The formulation generally contains fungal diastase, which acts as an amylase to aid in the breakdown of starch into simpler sugars, and pepsin, a proteolytic enzyme that degrades proteins into peptides. As a marketed product from Amox Pharmaceuticals, it serves as a therapeutic option for patients requiring exogenous digestive enzyme support to improve nutrient absorption and relieve gastrointestinal discomfort.

Brand names: ZymawinZymawin Drops
Other names: fungal diastase + pepsin

Beyond the preview

Go deeper on Zymawin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zymawin.

Explore the full profile